AxoGen, Inc. to Meet with Dr. Alejandro Toledo, Former President of Peru and Director of Global Center for Development and Democracy, During United Nations Meeting
Co-Founder & Vice President, John P. Engels to Discuss AxoGen’s Efforts to Expand International Presence
ALACHUA, FL - July 13, 2015 – AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company dedicated to peripheral nerve repair, announced today that Co-Founder and Vice President John P. Engels will meet with Dr. Alejandro Toledo, former President of Peru and Director of the Global Center for Development and Democracy, on Monday, July 13th at the United Nations in New York City. During the private meeting, Mr. Engels and President Toledo will discuss strategic avenues to bring AxoGen’s portfolio of peripheral nerve solutions to Peru, providing for the first time options for Peruvian citizens with nerve injuries and damage.
“Peru is an amazing country with incredible economic potential and a lack of peripheral nerve repair solutions. We’re very honored and excited to have the opportunity to be collaborating with President Toledo to develop AxoGen’s entry into this exciting market. This effort is part of our strategy to build the contribution of revenue from international markets,” stated Mr. Engels.
"In Latin America we are striving for a just, sustainable and prosperous but shared society. A society that preserves its culture and beautiful people, but yet can transform to globalization and the world stage. Economic growth combined with social improvement is our social accelerator, and economic stimulation through private sector partnership is a component to achieving this goal.” commented President Toledo.
About Dr. Alejandro Toledo
Dr. Alejandro Toledo (Stanford Ph.D) was democratically elected President of Peru in 2001. After finishing his term as President, Toledo returned to Stanford, where he was a Distinguished Fellow in Residence at the University's Center for Advanced Study in the Behavioral Sciences, and also a Payne Distinguished Visiting Lecturer at the Freeman Spogli Institute's Center on Democracy, Development, and the Rule of Law.
Simultaneously, Dr. Toledo founded and continues to serve as the President of the Global Center for Development and Democracy in Washington, DC. In 2009–2010, Dr. Toledo was a Distinguished Visiting Scholar at the School of Advanced International Studies at Johns Hopkins University in Washington, D.C., and also a Non-Resident Senior Fellow in Foreign Policy and Global Economy and Development at the Brookings Institution. In recent years, Dr. Toledo has published on policy-oriented academic issues related to Economic Growth, Inclusiveness and Democracy.
For more information on the Global Center for Development and Democracy, visit http://cgdd.org/en/
About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance® Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.
To learn more about AxoGen and to sign up for news alerts, visit www.AxoGenInc.com.
Cautionary Statement Concerning Forward-Looking Statements
This Press Release contains "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations or predictions of future conditions, events or results based on various assumptions and management's estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as "expects", "anticipates", "intends", "plans", "believes", "seeks", "estimates", "projects", "forecasts", "continue", "may", "should", "will" variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen's business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen's filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact:
AxoGen, Inc.
Lee Robert “Bob” Johnston, Chief Financial Officer
(P) 386.462.6856
InvestorRelations@AxoGenInc.com
www.axogeninc.com
Media Contact:
Matthew BIRD, President
1-800-PublicRelations, Inc.
(P) 646.401.4499
(O) 800.782.6185
matt.bird@1800pr.com
www.1800pr.com
Released July 13, 2015